

# Epiretinal Membrane

[View the current Epiretinal Membrane InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Epiretinal_Membrane.html) (PDF)

([http://www.bioportfolio.com/indepth/Epiretinal\\_Membrane.html](http://www.bioportfolio.com/indepth/Epiretinal_Membrane.html)) - Regularly Updated.

## Recent Publications on Epiretinal Membrane:



- [Ability of New Vital Dyes to Stain Intraocular Membranes and Tissues in Ocular Surgery.](#)  
*PURPOSE:* To evaluate the ability of novel dyes to stain lens capsule (LC),...10th November, 2009  
Vision Institute (IPEPO), Department of Ophthalmology, Federal University- Am J Ophthalmol. 2009 Nov 5. ([DOI Direct Link](#))
- [Optic disc pit maculopathy treated with vitrectomy, internal limiting membrane peeling, and gas tamponade: A report of two cases.](#)  
To present the outcomes of various retinal conditions treated with the...5th November, 2009  
- Eur J Ophthalmol. 2009 Sep-Oct;19(5):897; author reply 897-8.
- [Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis.](#)  
*Purpose.* Ocular toxoplasmosis is associated with vitreoretinal...3rd November, 2009  
Department of Ophthalmology, Hospital Clinic de Barcelona, Universidad de- Eur J Ophthalmol. 2009 Nov-Dec;19(6):1040-4.
- [Epiretinal membrane in a 12-year-old immunocompetent girl with cytomegalovirus infection.](#)  
*Purpose.* To report the case of a 12-year-old immunocompetent girl...3rd November, 2009  
Dipartimento di Scienze per la Salute, Universita degli Studi del Molise,- Eur J Ophthalmol. 2009 Nov-Dec;19(6):1099-102.
- [A 27-Gauge Instrument System for Transconjunctival Sutureless Microincision Vitrectomy Surgery.](#)  
*OBJECTIVES:* To evaluate the efficiency, preliminary safety, and...3rd November, 2009  
Department of Ophthalmology, Osaka University Medical School, Suita,- Ophthalmology. 2009 Oct 30.  
([DOI Direct Link](#))
- [Revisiting transconjunctival sutureless 25-gauge vitrectomy: still worthwhile?](#)  
To present the outcomes of various retinal conditions treated with the...29th October, 2009  
Vitreoretina Service, Flinders Eye Centre, Flinders University, Adelaide,- Clin Experiment Ophthalmol. 2009 Sep;37(7):649-53. ([DOI Direct Link](#))
- [TWENTY-THREE-GAUGE AND 20-GAUGE VITRECTOMY IN EPIRETINAL MEMBRANE SURGERY.](#)  
*PURPOSE::* The purpose of this study was to investigate the safety profile...17th October, 2009  
From the Department of Ophthalmology, Medical University, Graz, Austria.- Retina. 2009 Oct 14. ([DOI Direct Link](#))
- [Comparison of macular function and visual fields after membrane blue or infracyanine green staining in vitreoretinal surgery.](#)  
*BACKGROUND:* To compare possible toxic effects of membrane blue and...14th October, 2009  
Department of Ophthalmology, The Ludwig Boltzmann Institute for Retinology- Graefes Arch Clin Exp Ophthalmol. 2009 Oct 13. ([DOI Direct Link](#))

- [Intraoperative use of handheld spectral domain optical coherence tomography imaging in macular surgery.](#)  
*PURPOSE: To describe the intraoperative use of handheld spectral domain...*14th October, 2009  
Department of Ophthalmology, Duke University Eye Center, Durham, NC 27710,- Retina. 2009 Nov-Dec;29(10):1457-68. ([DOI Direct Link](#))
- [Vision-related quality of life and visual function following vitrectomy for various vitreoretinal disorders.](#)  
*Purpose: To investigate vision-related quality of life (VR-QOL) in...*10th October, 2009  
Ophthalmology, Clinical Medicine, University of Tsukuba, Tsukuba, Japan.- Invest Ophthalmol Vis Sci. 2009 Oct 8. ([DOI Direct Link](#))
- [A case of primary intraocular lymphoma treated by intravitreal methotrexate.](#)  
*A 40-year-old female visited our clinic for visual disturbance of the...*2nd October, 2009  
Department of Ophthalmology, Daegu Fatima Hospital, Daegu, Korea.- Korean J Ophthalmol. 2009 Sep;23(3):210-4. Epub 2009 Sep 8. ([DOI Direct Link](#))
- [A case of accidental macular injury by Nd: YAG laser and subsequent 6 year follow-up.](#)  
*Here, we report the case of a patient who sustained Nd: YAG laser macular...*2nd October, 2009  
Department of Ophthalmology, School of Medicine, Kyungpook National- Korean J Ophthalmol. 2009 Sep;23(3):207-9. Epub 2009 Sep 8. ([DOI Direct Link](#))
- [\[25-Gauge transconjunctival vitrectomy in a case of bilateral epiretinal membrane associated with a Terson syndrome\]](#)  
*The formation of epiretinal membranes associated with proliferative...*23rd September, 2009  
Service d'Ophtalmologie IV, CHNO des XV-XX, Paris, France.- J Fr Ophtalmol. 2009 Apr;32(4):268-72. Epub 2009 Mar 27. ([DOI Direct Link](#))
- [Anatomic and functional outcome after 23-gauge vitrectomy, peeling, and intravitreal triamcinolone for idiopathic macular epiretinal membrane.](#)  
*PURPOSE: To report both the functional and anatomic outcome and safety...*8th September, 2009  
Hopital Ophtalmique Jules Gonin, University of Lausanne, Lausanne,- Retina. 2009 Sep;29(8):1119-27. ([DOI Direct Link](#))
- [Mechanism of Visual Sensations Experienced during Pars Plana Vitrectomy under Retrobulbar Anesthesia.](#)  
*Purpose: To investigate the visual sensations experienced by patients...*5th September, 2009  
Department of Ophthalmology, Keio University School of Medicine, Tokyo,- Ophthalmologica. 2009 Sep 1;224(2):103-108. ([DOI Direct Link](#))

## Epiretinal Membrane Patents:



- 5112328- [Method and apparatus for laser surgery](#)
- 6200810- [Mutants of the Rb and p53 genes and uses thereof](#)
- 6210357- [Apparatus for performing surgery inside the human retina using fluidic internal limiting membrane \(ILM\) separation \(films\)](#)
- 6213998- [Laser surgical cutting probe and system](#)
- 6242480- [Ophthalmic viscoelastic compositions](#)
- 6313155- [Composition and method for treating macular disorders](#)
- 6331523- [Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5](#)

- 6380261- [Calcium blockers to treat proliferative vitreoretinopathy](#)
- 6395294- [Method of visualization of the vitreous during vitrectomy](#)
- 6433007- [Methods for the prevention and treatment of post-surgical complications](#)
- 6458120- [Laser surgical cutting probe and system](#)
- 6124259- [Method for treating ophthalmic disorders with IGFBP](#)
- 6024719- [Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane \(ILM\) separation \(FILMS\)](#)
- 6013628- [Method for treating conditions of the eye using polypeptides](#)
- 5292509- [Method for the disinsertion of vitreous body by an enzyme which disrupts or degrades chondroitin sulfate proteoglycan](#)
- 5405749- [Method for identifying and purifying a cancer associated retinopathy autoantigen, and testing patient serum for the autoantibody to the autoantigen](#)
- 5753522- [Purified protein for identifying a cancer-associated retinopathy autoantibody](#)
- 5767079- [Method of treating ophthalmic disorders using TGF-.beta.](#)
- 5811438- [Esters and amides of non-steroidal anti-inflammatory carboxylic acids which may be used as anti-oxidants, 5-lipoxygenase inhibitors and non-steroidal anti-inflammatory products](#)
- 5811453- [Viscoelastic compositions and methods of use](#)
- 5892570- [Method and apparatus for measuring and correcting metamorphopsia](#)
- 5925673- [Benzofurans and benzopyrans as cytoprotective agents](#)
- 5928663- [Intraocular perfluorocarbon compositions and surgical methods of using same](#)
- 5969120- [Mutants of the RB and P53 genes](#)
- 6573280- [Calcium blockers to treat proliferative vitreoretinopathy](#)
- 6590086- [Mutants of the Rb and p53 genes and uses thereof](#)
- 7338167- [Retinal imaging system](#)
- 7365172- [Loop peptide and TGF.alpha. for stimulating stem cell proliferation and migration](#)
- 7404969- [Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- 7442375- [Compositions of beta-defensin inducing agents](#)
- 7442686- [Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions](#)
- 7444057- [Variable-wedge rotating-disk beam attenuator for ophthalmic endoilluminator](#)
- 7479481- [Treatment of ocular diseases and disorders using lantibiotic compositions](#)
- 7499624- [Ophthalmic Endoilluminator with Variable-Wedge Rotating-Disk Beam Attenuator](#)
- 7514099- [Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules](#)
- 7517864- [RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- 7329645- [TGF-.alpha. polypeptides, functional fragments and methods of use therefor](#)
- 7268137- [Ocular therapy](#)
- 7230032- [Calcium blockers to treat proliferative vitreoretinopathy](#)
- 6667173- [Nucleic acids encoding platelet derived growth factor-alpha receptors](#)
- 6677307- [TGF-.alpha. polypeptides, functional fragments and methods of use therefor](#)
- 6692526- [Ophthalmological surgery colorant and delivery system](#)
- 6696430- [Use of vital dye for facilitating surgical procedures for vitreo-retinal surgery](#)
- 6764683- [Loop peptide and TGF.alpha. for stimulating stem cell proliferation and migration](#)
- 6815418- [TGF-.alpha. polypeptides, functional fragments and methods of use therefor](#)
- 7060723- [Treating neurological disorders using selective antagonists of persistent sodium current](#)
- 7070619- [Ophthalmological surgery colorant and delivery system](#)
- 7176304- [RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid \(siNA\)](#)
- 7220000- [Methods, devices and systems for assessing eye disease](#)
- 7589057- [Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems](#)

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

